Opko Health Inc
$ 1.15
0.00%
24 Feb - close price
- Market Cap 912,850,000 USD
- Current Price $ 1.15
- High / Low $ 1.16 / 1.13
- Stock P/E N/A
- Book Value 1.70
- EPS -0.24
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.13 %
- 52 Week High 2.04
- 52 Week Low 1.11
About
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
Analyst Target Price
$3.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-07-31 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0 | 0.03 | -0.19 | -0.0949 | 0.01 | -0.03 | -0.01 | -0.12 | -0.09 | -0.11 | -0.03 | -0.02 |
| Estimated EPS | -0.0671 | -0.06 | -0.1133 | -0.11 | -0.1 | -0.09 | -0.09 | -0.09 | -0.09 | -0.1 | -0.07 | -0.08 |
| Surprise | 0.0671 | 0.09 | -0.0767 | 0.0151 | 0.11 | 0.06 | 0.08 | -0.03 | 0 | -0.01 | 0.04 | 0.06 |
| Surprise Percentage | 100% | 150% | -67.6964% | 13.7273% | 110% | 66.6667% | 88.8889% | -33.3333% | 0% | -10% | 57.1429% | 75% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OPK
2026-02-24 21:52:11
OPKO Health Inc is projected to report a loss of 7 cents per share. This information comes from an earnings preview provided by Refinitiv and Reuters. The article is a brief financial news piece focusing on the company's expected earnings.
2026-02-24 11:35:00
Opko Health, Inc. (OPK) is analyzed for its significant 209.42% potential upside, based on analyst target prices ranging from $1.60 to $8.50, with an average of $3.56. Despite current financial challenges such as a negative P/E ratio and cash burn, the healthcare company, focusing on diagnostics and pharmaceuticals, holds five out of seven buy ratings. Its strategic focus on innovative treatments and global presence are highlighted as potential catalysts for future growth, appealing to long-term investors with higher risk tolerance.
2026-02-21 16:23:33
Phillip Frost, CEO and Chairman of Opko Health, Inc. (NASDAQ:OPK), recently invested $444,300 in company stock, purchasing 500,000 shares at a weighted average price of $0.8886. This significant acquisition, bringing his total holdings to over 210 million shares, is seen as a strong vote of confidence despite the company's volatile stock price and negative P/E ratio. Analysts predict Opko Health will be profitable this year, and the company is trading near its 52-week low.
2026-02-20 13:56:31
Seven brokerages have issued a "Hold" recommendation for OPKO Health, Inc. (NASDAQ:OPK), with an average 12-month price target of $2.2833. Analysts' ratings range from "sell" to "strong buy," reflecting varied opinions on the stock. Institutional investors have significantly adjusted their positions, with notable increases in holdings by major firms.
2026-02-19 17:01:31
OPKO Health (OPK) is positioned for growth in the coming quarters, driven by the potential of its renal therapy RAYALDEE and strategic partnerships. Despite concerns about competition and over-reliance on RAYALDEE, the company's clinical pipeline includes several advanced programs in oncology, hypoparathyroidism, and metabolic disorders. OPKO Health anticipates 30% growth for fiscal 2026 and has undertaken divestitures to streamline operations and strengthen its balance sheet.
2026-02-19 08:57:52
OPKO Health (OPK) is expected to announce its Q4 2025 earnings after market close on Thursday, February 26th, with projected EPS of ($0.07) and revenue of $139.757 million. The company has seen significant insider activity, including CEO Phillip Frost's purchase of 580,000 shares, bringing insider ownership to 49.69%. Analysts currently hold a consensus "Hold" rating for OPK, with a price target of $2.28.
